HCC update

13:31

Immunicum AB (publ) today reported updated safety and survival data in the ongoing phase I/II study with INTUVAX in patients with primary liver cancer. Six out of eight included liver cancer patients were able to receive all three vaccine doses with encouraging survival data for four of these six fully vaccinated patients.